Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Eylea
Eylea is indicated for adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to diabetic macular oedema (DME); visual impairment due to myopic choroidal neovascularisation (myopic CNV).
View on EMAColorectal Neoplasms
Pneumonia, Bacterial
Overactive Bladder
Chronic Kidney Disease
Oral Contraceptive